Natural borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage
Authors Liu WJ, Yin YB, Sun JY, Feng S, Ma JK, Fu XY, Hou YJ, Yang MF, Sun BL, Fan CD
Received 17 May 2018
Accepted for publication 17 July 2018
Published 4 September 2018 Volume 2018:11 Pages 5429—5439
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Tohru Yamada
Wen-Jian Liu,1,* Yi-Bo Yin,1,* Jing-Yi Sun,2,* Sai Feng,3 Jin-Kui Ma,4 Xiao-Yan Fu,5 Ya-Jun Hou,5 Ming-Feng Yang,5 Bao-Liang Sun,1,5 Cun-Dong Fan5
1Department of Neurology, Affiliated Hospital of Taishan Medical University, Taian, Shandong, People’s Republic of China; 2Department of Orthopaedics, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Gangwon, Korea; 3Guangzhou New BenFu Technology Co., Ltd, Guangzhou, Guangdong, People’s Republic of China; 4Faculty of Bioresource Sciences, Akita Prefectural University, Shimoshinjo-Nakano, Akita-shi, Akita, Japan; 5Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong, People’s Republic of China
*These authors contributed equally to this work
Background: Temozolomide (TMZ)-based chemotherapy represents an effective way for treating human glioma. However, its clinical application is limited because of its side effects and resistance to standard chemotherapy. Hence, the search for novel chemosensitizers to augment their anticancer efficiency has attracted much attention. Natural borneol (NB) has been identified as a potential chemosensitizer in treating human cancers. However, the synergistic effect and mechanism of NB and TMZ in human glioma have not been investigated yet.
Materials and methods: U251 human glioma cells were cultured, and the cytotoxicity and apoptosis of NB and/or TMZ were examined by MTT assay, flow cytometric analysis and Western blot. Nude mice tumor model was also employed to evaluate the in vivo anticancer effect and mechanism.
Results: The results showed that the combined treatment of NB and TMZ more effectively inhibited human glioma growth via triggering mitochondria-mediated apoptosis in vitro, accompanied by the caspase activation. Combined treatment of NB and TMZ also caused mitochondrial dysfunction through disturbing Bcl-2 family expression. Further investigation revealed that NB enhanced TMZ-induced DNA damage through inducing reactive oxide species (ROS) overproduction. Moreover, glioma tumor xenograft growth in vivo was more effectively inhibited by the combined treatment with NB and TMZ through triggering apoptosis and anti-angiogenesis.
Conclusion: Taken together, our findings validated that the strategy of using NB and TMZ could be a highly efficient way to achieve anticancer synergism.
Keywords: glioma, borneol, temozolomide, DNA damage, apoptosis
Corrigendum for this paper has been published.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]